What is a stock summary page? Click here for an overview.
Business Description
Lexaria Bioscience Corp
NAICS : 325412
SIC : 2834
ISIN : US52886N3070
Description
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 61.97 | |||||
| Equity-to-Asset | 1 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 37.52 | |||||
| Beneish M-Score | -2.87 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -39.2 | |||||
| 3-Year EBITDA Growth Rate | 28.7 | |||||
| 3-Year EPS without NRI Growth Rate | 28.3 | |||||
| 3-Year FCF Growth Rate | 23.4 | |||||
| 3-Year Book Growth Rate | -39.7 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 43.28 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 81.82 | |||||
| 9-Day RSI | 70.64 | |||||
| 14-Day RSI | 62.67 | |||||
| 3-1 Month Momentum % | -33.03 | |||||
| 6-1 Month Momentum % | -52.56 | |||||
| 12-1 Month Momentum % | -62.53 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 29.62 | |||||
| Quick Ratio | 29.62 | |||||
| Cash Ratio | 27.24 | |||||
| Days Sales Outstanding | 35.99 | |||||
| Days Payable | 38471 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -40.3 | |||||
| Shareholder Yield % | -23.52 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 99.4 | |||||
| Operating Margin % | -1469.82 | |||||
| Net Margin % | -1473.04 | |||||
| FCF Margin % | -1346.28 | |||||
| ROE % | -95.83 | |||||
| ROA % | -94.69 | |||||
| ROIC % | -518.67 | |||||
| 3-Year ROIIC % | 40.49 | |||||
| ROC (Joel Greenblatt) % | -1347.01 | |||||
| ROCE % | -98.78 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 53.45 | |||||
| PB Ratio | 3.34 | |||||
| Price-to-Tangible-Book | 3.53 | |||||
| EV-to-EBIT | -3.23 | |||||
| EV-to-Forward-EBIT | -1.27 | |||||
| EV-to-EBITDA | -3.27 | |||||
| EV-to-Revenue | 47.44 | |||||
| EV-to-Forward-Revenue | 40.61 | |||||
| EV-to-FCF | -3.37 | |||||
| Price-to-GF-Value | 1.02 | |||||
| Price-to-Median-PS-Value | 0.54 | |||||
| Price-to-Net-Current-Asset-Value | 3.74 | |||||
| Price-to-Net-Cash | 4.07 | |||||
| Earnings Yield (Greenblatt) % | -30.96 | |||||
| FCF Yield % | -20.38 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:LEXX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lexaria Bioscience Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.497 | ||
| EPS (TTM) ($) | -0.5 | ||
| Beta | 0.93 | ||
| 3-Year Sharpe Ratio | 0.18 | ||
| 3-Year Sortino Ratio | 0.35 | ||
| Volatility % | 78.24 | ||
| 14-Day RSI | 62.67 | ||
| 14-Day ATR ($) | 0.157573 | ||
| 20-Day SMA ($) | 1.46735 | ||
| 12-1 Month Momentum % | -62.53 | ||
| 52-Week Range ($) | 1.15 - 4.44 | ||
| Shares Outstanding (Mil) | 17.55 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lexaria Bioscience Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lexaria Bioscience Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Lexaria Bioscience Corp Frequently Asked Questions
What is Lexaria Bioscience Corp(LEXX)'s stock price today?
The current price of LEXX is $1.87. The 52 week high of LEXX is $4.44 and 52 week low is $1.15.
When is next earnings date of Lexaria Bioscience Corp(LEXX)?
The next earnings date of Lexaria Bioscience Corp(LEXX) is 2025-04-09 Est..
Does Lexaria Bioscience Corp(LEXX) pay dividends? If so, how much?
Lexaria Bioscience Corp(LEXX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers